PRTA – prothena corporation plc - ordinary shares (US:NASDAQ)
Stock Stats
News
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma [Yahoo! Finance]
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Prothena to Participate in Upcoming Healthcare Conferences
Form ARS PROTHENA CORP PUBLIC For: Dec 31
Form DEFA14A PROTHENA CORP PUBLIC
Form DEF 14A PROTHENA CORP PUBLIC For: May 14
Form 4 PROTHENA CORP PUBLIC For: Mar 01 Filed by: Ford David A
Form 3 PROTHENA CORP PUBLIC For: Mar 01 Filed by: Ford David A
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.